93 studies found for:    "Hyperlipoproteinemia type 2"
Show Display Options
Rank Status Study
1 Terminated Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
Conditions: Hyperlipoproteinemia Type II;   Homozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo
2 Completed Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
Conditions: Hyperlipoproteinemia Type II;   Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo for Anacetrapib
3 Recruiting Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Conditions: Familial Hypercholesterolemia;   Lipid Disorder
Intervention:
4 Completed
Has Results
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
5 Completed An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
6 Recruiting Russian Familial Hypercholesterolemia Registry
Condition: Familial Hypercholesterolemia
Intervention:
7 Unknown  Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils
Conditions: Hypertriglyceridaemia;   Familial Hypercholesterolaemia
Interventions: Dietary Supplement: Fish oil capsule;   Drug: HMG Coenzyme reductase
8 Active, not recruiting Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: CER-001
9 Completed An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
Condition: Familial Hypercholesterolaemia
Intervention: Drug: rosuvastatin calcium
10 Active, not recruiting Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
Condition: Familial Hypercholesterolemia
Intervention: Drug: lomitapide
11 Terminated Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
Condition: Familial Hypercholesterolemia
Intervention: Drug: Implitapide
12 Terminated Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
Condition: Familial Hypercholesterolemia
Intervention: Drug: Implitapide
13 Withdrawn Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
Condition: Familial Hypercholesterolemia
Interventions: Drug: APL180;   Drug: Placebo
14 Recruiting The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Condition: Homozygous Familial Hypercholesterolemia
Intervention:
15 Completed
Has Results
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
16 Completed Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
Conditions: Heterozygous Familial Hypercholesterolemia;   Mixed Dyslipidemia
Intervention: Drug: Fluvastatin
17 Recruiting A 52 Week Study To Assess The Use Of RN316 (PF-04950615) In Subjects With Heterozygous Familial Hypercholesterolemia
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: PF-04950615;   Other: Placebo
18 Unknown  Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
Condition: Heterozigous Familial Hypercholesterolemia
Intervention: Drug: Statins and Ezetimibe
19 Not yet recruiting French Observatory of Familial Hypercholesterolemia in Cardiology
Condition: Familial Hypercholesterolemia
Intervention:
20 Completed Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia
Conditions: Dyslipidemia;   Familial Hypercholesterolemia
Interventions: Dietary Supplement: Lactobacillus paracasei B21060;   Other: low satured diet

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years